Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone for Chronic Itch in Atopic Dermatitis
NCT04325802Phase 2Withdrawn
- Sponsor
- University of Minnesota
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone in atopic dermatitis (AD) and pruritus (3 arms), sponsored by University of Minnesota. Primary endpoint: Change in Itch Intensity at 1 week. Planned start Dec 2022; status: withdrawn.
02
Drugs
naltrexone
03
Conditions
atopic dermatitis (AD)pruritus
Beyond the preview
Go deeper on NCT04325802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325802.